CompletedPhase 2

Study of Jitongning Tablet to Treat Spondyloarthritis

China238 participantsStarted 2019-06-11

Plain-language summary

This study is to investigate the efficacy and safety of Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis (SpA) patients and to explore the optimal dosage.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. BASDAI score ≥ 4;
✓. In the assessment of pain numerical rating scale (NRS), spine pain NRS ≥ 4;

What they're measuring

ASAS 20 response

Timeframe: 12 weeks

Trial details

NCT IDNCT03932019

SponsorTasly Pharmaceutical Group Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-06-20

View on ClinicalTrials.gov More Spondyloarthritis trials